SMARCA4 Gene Mutation clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
open to eligible people ages 18 years and up
This is a Phase 1 dose-escalation study of PRT3789, a SMARCA2 degrader, in participants with advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The purpose of this study is to evaluate the safety,…
at UC Davis UCLA UCSF
Our lead scientists for SMARCA4 Gene Mutation research studies include Edward B. Garon, MD, MS Varun Monga.
Last updated: